Inactivation of Wild Poliovirus with β-Propiolactone

Area of Science:

• Virology
• Vaccine Development
• Immunology

Background:

• Traditional antiviral vaccine production involves virus inactivation using physical or chemical agents.
• Formaldehyde inactivation of poliovirus requires prolonged incubation, increasing risks associated with the inactivating agent.

Purpose of the Study:

• To evaluate beta-propiolactone (BPL) as a rapid and effective inactivating agent for poliovirus.
• To compare the immunogenicity of BPL-inactivated poliovirus with formaldehyde-inactivated controls.

Main Methods:

• Poliovirus inactivation using 0.2% BPL at 4°C for 24 hours and 37°C for 3 hours.
• Confirmation of inactivation completeness using Vero cell culture.
• Assessment of immunogenicity in guinea pigs through neutralizing antibody tests.

Main Results:

• Both BPL inactivation methods yielded samples that retained immunogenic properties.
• BPL-inactivated poliovirus demonstrated sufficient D-antigen levels and elicited comparable or superior neutralizing antibodies to formaldehyde-inactivated controls.
• Inactivation at 37°C was faster than at 4°C, which showed a gradual virus titer decrease.

Conclusions:

• Beta-propiolactone (BPL) is a viable alternative to formaldehyde for inactivated polio vaccine (IPV) production.
• BPL provides rapid poliovirus inactivation while preserving essential immunogenic characteristics.
• Guinea pig studies confirmed the immunogenicity of BPL-treated poliovirus.